和黄医药（HCM）今日盘中大涨5.08%，引起市场广泛关注。据悉，多家券商发布研报，看好公司未来发展前景。
中金公司维持和黄医药"跑赢行业"评级，目标价30港元，较当前股价有24.7%的上行空间。尽管公司2025年上半年业绩低于预期，但中金认为下半年公司收入有望改善。主要利好因素包括：呋喹替尼海外销售额同比增长25%，已在超过30个国家和地区获批上市；赛沃替尼新适应症获批；以及公司创新管线进展顺利。
此外，和黄医药正积极推进抗体靶向偶联药物（ATTC）项目，首个候选药物HMPL-A251计划于2025年年底进入临床开发。分析师认为，ATTC管线的加速推进有望为公司带来更多合作和授权机会。太平洋证券也维持对和黄医药的"买入"评级，进一步增强了投资者信心。这些积极因素共同推动了和黄医药股价的强劲上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.